NEWS
New Feature!!!! University Subject Rankings in 12 branches
FOR SCIENTIST REGISTRATION FOR INSTITUTIONAL BULK REGISTRATION
FOR EDIT YOUR UNIVERSITY / INSTITUTION PAGE
Some differences of the AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
List without CERN, Statistical Data etc. Only in AD Scientific Index
New Feature!!!! University Subject Rankings in 12 branches
AD
Scientific Index 2024
About Us
Methodology
Compare & Choose
Contact - FAQ
login
Login
person_add
Register
insights
i10 Productivity Rankings
format_list_numbered
Citation Rankings
school
University Rankings
subject
University Subject Rankings
insights
Subject Rankings
place
Country Rankings
format_list_numbered
Top 100 Scientists
format_quote
Top 100 Institutions
local_fire_department
Country Top Lists
Mark Raffeld
National Institutes of Health - Bethesda, Maryland / United States
Medical and Health Sciences / Pathology
AD Scientific Index ID: 4386791
Edit Form
Registration, Add Profile,
Premium Membership
Ranking &
Analysis
Job
Experiences (0)
Education
Information (0)
Published Books (0)
Book Chapters (0)
Articles (0)
Presentations (0)
Lessons (0)
Projects (0)
Congresses (0)
Editorship, Referee &
Scientific Board (0 )
Patents /
Designs (0)
Academic Grants
& Awards (0)
Artistic
Activities (0)
Certificate / Course
/ Trainings (0)
Association &
Society Memberships (0)
Contact, Office
& Social Media
person_outline
Mark Raffeld's MOST POPULAR ARTICLES
1-)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytesME Dudley, JR Wunderlich, PF Robbins, JC Yang, P Hwu, ...Science 298 (5594), 850-854, 200235002002
2-)
Gene-expression profiles in hereditary breast cancerI Hedenfalk, D Duggan, Y Chen, M Radmacher, M Bittner, R Simon, ...New England Journal of Medicine 344 (8), 539-548, 200121032001
3-)
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1PF Robbins, RA Morgan, SA Feldman, JC Yang, RM Sherry, ME Dudley, ...Journal of Clinical Oncology 29 (7), 917, 201117362011
4-)
Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric …JN Kochenderfer, ME Dudley, SH Kassim, RPT Somerville, RO Carpenter, ...Journal of clinical oncology 33 (6), 540-549, 201519342015
5-)
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19JN Kochenderfer, WH Wilson, JE Janik, ME Dudley, M Stetler-Stevenson, ...Blood, The Journal of the American Society of Hematology 116 (20), 4099-4102, 201016502010
ARTICLES
Add your articles
We use cookies to personalize our website and offer you a better experience. If you accept cookies, we can offer you special services.
Cookie Policy
Accept